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Background: Human papillomavirus (HPV) vaccines were first licensed as a three-dose series; a two-dose
series is now recommended in some age groups and there is interest in possible one-dose vaccination.
Methods: We conducted a systematic literature review of HPV vaccine effectiveness by number of doses,
including assessment of biases and impact of varying buffer periods (time between vaccination and out-
come counting).
Results: Of 3787 articles identified, 26 full articles were assessed and 14 included in our review. All stud-
ies were conducted within the context of recommended three-dose schedules of bivalent (3) or quadri-
valent HPV vaccine (11). Two evaluated effectiveness for prevention of HPV prevalence, six anogenital
warts, and six abnormal cervical cytology or histology. Many studies found differences between three-,
two- and one-dose vaccine recipients, indicating possible differences in HPV exposure prior to vaccina-
tion or in risk behavior. Adjusted or stratified analyses were conducted to control for potential confound-
ing. All studies found significant vaccine effectiveness with three doses, 11 with two doses at various
intervals, and six with one dose. Most studies showed a relationship (not always statistically significant)
between effectiveness and number of doses, with greater decreases in HPV-related outcomes with three,
followed by two and one dose(s). Few studies conducted formal comparisons of three vs fewer doses.
Three of four studies that examined buffer periods found higher effectiveness and a smaller difference
by number of doses with longer periods.
Conclusion: Most post-licensure studies report highest effectiveness with three doses; some found no
statistically significant difference between two and three doses. Additionally, almost half found some
effectiveness with one dose. Several biases impact estimates, with most biasing two- and one-dose
results away from showing effectiveness. Future effectiveness studies, examining persons vaccinated
prior to sexual activity and using methods to reduce potential sources of bias, can help inform vaccination
policy.
Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).
1. Background
All three currently available human papillomavirus (HPV) vacci-
nes were originally evaluated in clinical trials, licensed and recom-
mended as a three-dose schedule (0, 1–2 and 6 months). However,
interest in a reduced dose schedule arose soon after the first vacci-
nes were licensed [1]. The high immunogenicity and efficacy
observed in clinical trials with three doses and a post hoc analysis
of one clinical trial stimulated interest in fewer doses [2]. Immuno-
genicity studies have been conducted with these available HPV
vaccines and show non-inferior antibody response after two doses,
administered 6–12 months apart, in young adolescents compared
with three doses in women in the age group for which efficacy
was demonstrated in clinical trials [3–5]. In 2014, the World
Health Organization changed its guidance for number of doses
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and recommended a two-dose HPV vaccination schedule for girls
starting the series at age 9 through 14 years [6]. In 2016, the Advi-
sory Committee on Immunization Practices recommended a two-
dose schedule in the United States for this age group [7]. Many
countries in Europe, the Americas, and countries funded by Gavi,
the Vaccine Alliance, either changed from a three-dose to a two-
dose schedule in this age group, or introduced HPV vaccination
with a two-dose schedule [8].
While immunogenicity trials have demonstrated non-
inferiority of two HPV vaccine doses in young adolescents and
were accepted by regulatory agencies, many effectiveness studies
conducted in real world programs have largely shown lower effec-
tiveness with fewer than three doses. We conducted a systematic
review of the literature to: (1) summarize evidence about effec-
tiveness of HPV vaccination by the number of doses, as measured
in post-licensure studies, and (2) explore and discuss the main lim-
itations and challenges of these studies.
2. Methods
2.1. Study selection
Studies were eligible if they fulfilled the following inclusion cri-
teria: (1) reported effectiveness of HPV vaccination (bivalent or
quadrivalent vaccine) on HPV infections, anogenital warts, or cer-
vical abnormalities (based on cytological or histopathological
results); (2) assessed effectiveness of HPV vaccination by the num-
ber of doses received (one, two, or three). We excluded studies if
vaccine was administered as part of a randomized controlled trial
(e.g., post hoc evaluations of clinical trials).
We searched Medline and Embase databases from January 1,
2007 to June 15, 2017 using a combination of Medical Subject
Headings (MeSH) terms, title or abstract words, without restriction
on the language of publications: (‘‘papillomavirus vaccines”, ‘‘HPV
vaccine”, ‘‘HPV vaccination”, ‘‘papillomavirus vaccine”, or ‘‘papillo-
mavirus vaccination”) and (‘‘program evaluation”, ‘‘immunization
programs”, ‘‘population surveillance”, ‘‘sentinel surveillance”, ‘‘in-
cidence”, ‘‘prevalence”, ‘‘rate”, ‘‘rates”, ‘‘effectiveness”, ‘‘doses”)
and (‘‘papillomavirus infections”, ‘‘HPV”, ‘‘uterine cervical neo-
plasms”, ‘‘cervical intraepithelial neoplasia”, ‘‘HPV related dis-
eases”, ‘‘condylomata acuminata”, ‘‘genital warts”). The selection
of eligible articles was performed independently by MD and NP
on title and abstract first, and secondly on the full-text article.
2.2. Data extraction
Two authors (NP and LM) independently extracted the main
study characteristics and outcomes using standardized forms.
Any discrepancy between the two independent extractions was
resolved by MD. The main study characteristics included the coun-
try, study design, age of study population at vaccination and out-
come assessment, sample size according to the number of doses
received, case definition, and statistical analyses (procedure used
to assign the number of doses, and adjustment for potential con-
founders). Information on use of buffer periods (lag time between
vaccination and counting of outcomes) was also collected. Buffer
periods delay the case counting to attempt to exclude conditions
caused by a prevalent infection at the time of vaccination.
Sources of bias in post-licensure studies examining the impact
of HPV vaccination by number of doses include: (1) differences in
the characteristics and age at vaccination between groups vacci-
nated with different number of doses; (2) likelihood of prevalent
infection at vaccination; and (3) interval between the first and sec-
ond dose of the HPV vaccine among two-dose vaccine recipients.
Therefore, information on how authors dealt with these potential
sources of bias was also extracted. Since one of the aims of this sys-
tematic review was to discuss the limitations of these studies, no
studies were excluded on the basis of the methodological quality.
The main outcome was effectiveness of HPV vaccination com-
paring the incidence or prevalence of HPV-related endpoints
between individuals vaccinated with different number of doses
(three vs none, two vs none, one vs none, three vs two, three vs
one, two vs one) of quadrivalent or bivalent vaccine. Results are
presented as crude or adjusted risk ratios (RR) or odds ratios
(OR). Of note, because eligible studies used different buffer periods
or age groups at vaccination and at outcome assessment, it was not
possible to pool results from the studies.
3. Results
The literature search identified 3787 articles, from which 26 full
articles were assessed. After reading full texts, 12 articles were
excluded, leaving 14 in our review (Fig. 1) [9–22]. These publica-
tions were from eight different countries, published from 2013
through 2017: Australia (three), Scotland (three), United States
(two), Sweden (two), and one each from Belgium, Canada, Den-
mark, and Spain (Table 1). All evaluations were conducted within
the context of a recommended three-dose schedule of either biva-
lent HPV vaccine (three) or quadrivalent HPV vaccine (eleven).
Articles included analyses of effectiveness for prevention of HPV
infection (two), anogenital warts (six), and cervical cytological or
histological abnormalities (six) (Table 2 and Appendix).
Recognizing the potential for confounding, all investigators
attempted to control for or stratified by potentially important vari-
ables, such as age at vaccination; however, limited other variables
were available in most studies (Table 1). Four studies also evalu-
ated the impact of different buffer periods and four evaluated dif-
ferent intervals between doses for two-dose vaccine recipients.
3.1. HPV prevalence
The two studies that reported vaccine effectiveness for reduc-
tion of prevalent vaccine type infection (HPV 16 or 18) were both
from Scotland, conducted in the context of a three-dose bivalent
HPV vaccination program that had achieved high coverage in the
routine and catchup target age groups. The studies used residual
cervical screening samples obtained at first screen of 20–21 year-
olds and national vaccine registry data. Most two-dose vaccine
recipients received doses at a one-month interval. Kavanagh
et al. found statistically significant effectiveness for three doses,
aOR = 0.43 (95% CI 0.34, 0.55); but not two doses, aOR = 0.68
(95% CI 0.42, 1.12); or one dose, aOR = 0.95 (95% CI 0.51, 1.76)
[9]. There were few one- or two-dose vaccine recipients. In the sec-
ond study, Cuschieri et al. over-selected women partially vacci-
nated [10]. Compared with three-dose vaccine recipients,
partially vaccinated women were older than those fully vaccinated
and differed by socioeconomic status. Statistically significant effec-
tiveness was found for three doses, aOR = 0.27 (95% CI 0.20, 0.37);
two doses, aOR = 0.45 (95% CI 0.29, 0.69); and one dose, aOR = 0.52
(95% CI 0.31, 0.83). Neither study performed a formal comparison
of effectiveness of three doses vs fewer doses; confidence intervals
for the effectiveness estimates of three, two and one dose(s)
overlapped.
3.2. Anogenital warts
The six evaluations of anogenital wart outcomes were retro-
spective cohort studies from five different countries that had intro-
duced quadrivalent HPV vaccination [11–16]. Only one study
presented characteristics of women by number of doses [12]
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although all studies adjusted analyses for age at vaccination and
some were able to adjust for educational level or markers of
socioeconomic status (Table 1). Most two-dose vaccine recipients
received doses separated by two months. Two studies also
included assessment of different buffer periods [11,14] and three
included assessment of different intervals between doses in two-
dose vaccine recipients [12,14,16].
Herweijer et al. evaluated vaccine effectiveness in Sweden using
data from national registries. The population evaluated included
girls and women vaccinated during a time of opportunistic vacci-
nation before HPV vaccination was incorporated into the routine
school-based program [11]. In the primary analyses, a three-
month buffer period was used before anogenital wart counting.
The effect of different buffer periods was examined and analyses
were stratified by age at vaccination (10–16 years and 17–19
years) and adjusted for attained age and parental education. There
was statistically significant effectiveness for three doses, aRR =
0.20 (95% CI 0.17, 0.23); two doses, aRR = 0.32 (95% CI 0.26,
0.40); and one dose, aRR = 0.54 (95% CI 0.43, 0.68). Vaccine effec-
tiveness was significantly higher for three compared with two or
one dose(s). However, there was no statistically significant differ-
ence between two and three doses with a buffer period > four
months, regardless of the age at vaccine initiation.
In a study conducted in Denmark using data from national reg-
istries, Blomberg et al. evaluated vaccine effectiveness among girls
and women vaccinated as part of a routine and catchup program.
Statistically significant effectiveness was found for one compared
with no dose, RR = 0.51 (95% CI 0.46, 0.56). Data were not reported
for effectiveness of three and two doses compared with no dose,
but the investigators found that anogenital warts occurred signifi-
cantly less frequently with each additional dose: two vs one, RR =
0.44 (95% CI 0.37, 0.51); three vs two, RR = 0.46 (95% CI 0.39, 0.54)
[12]. After adjustment for age at vaccination, maternal educational
level and income, and calendar time, effectiveness for three doses
remained significantly higher than for two doses. However, there
was no statistically significant difference between three and two
doses with an interval > four months between doses; the RR was
close to one with an interval of six months. This change in effec-
tiveness for three compared with two doses, with increasing inter-
val between doses, was observed for women who initiated
vaccination at age <16 years and 16 years.
Somewhat similar findings related to the effect of interval
between two doses were reported by Lamb et al. who examined
effectiveness of three compared with two doses using data from
Swedish national registries [16]. Higher effectiveness was observed
for three compared with two doses, when two doses were admin-
Fig. 1. Flow diagram of study selection process.
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Table 1
Characteristics of studies that evaluated HPV vaccine effectiveness by number of doses.
Endpoint/vaccine/
reference
Country Study design Study population
Age (years) at
Vaccination Case definition Statistical analyses
Vaccination Outcome N by dose
number
Assignment
of dose
number
Buffer
periodsa
(months)
Adjustment or stratification
HPV prevalence
Bivalent vaccine
Kavanagh et al.
(2014)
[9]
Scotland Cross-sectional study using screening
registry data
15–17 20–21 0: 3418
1: 55
2: 106
3: 1100
HPV 16 or 18 DNA positivity in liquid
based cytology samplesb
Final status 0 Birth year cohort, deprivation
score
Cuschieri et al.
(2016)
[10]
Scotland Cross-sectional study using screening
registry data with additional sampling of
women with < 3 doses
15–17 20–21 0: 3619
1: 177
2: 300
3: 1853
HPV 16 or 18 DNA positivity in liquid
based cytology samplesc
Final status 0 Birth year cohort, deprivation
score, age at first dose
Anogenital warts
Quadrivalent vaccine
Herweijer et al.
(2014)
[11]
Sweden Retrospective cohort study using
population-based health registries
10–19 10–24 0: 926,119
1: 115,197
2: 107,338
3: 89,836
First observed diagnosis: ICD-10 code
A63.0 or podophyllotoxin/ imiquimod
prescription
Time-
dependent
Final status
0 to 12 Age at first vaccination, age at
outcome, parental education
Blomberg et al.
(2015)
[12]
Denmark Retrospective cohort study using
population-based health national registries
12–27 12–27 0: 188,956
1: 55,666
2: 93,519
3: 212,549
First diagnosis: ICD-10 code A63.0 or
podophyllotoxin prescription
Time-
dependent
1 Age at vaccination, maternal
education disposable income,
calendar year
Dominiak-Felden
et al. (2015)
[13]
Belgium Retrospective cohort study using sick-fund/
insurance data
10–23 16–23 0: 63,180
1: 4020
2: 3587
3: 35,792
First prescription of imiquimod and
reimbursement
Time-
dependent
1 Age at first dose
Perkins et al.
(2017)
[14]
United
States
Retrospective cohort study using
commercial claims database
9–25 9–25 0: 201,933
1: 30,438
2: 36,583
3: 118,962
ICD-9 codesd Final status 0, 12 Age, regions, SES indicators,
calendar year, differential
observation periods
Navarro-Illana
et al. (2017)
[15]
Spain Retrospective cohort study using national
registries
14 14–19 0: NAe
1: NA
2: NA
3: NA
First diagnosis of ICD-9-CM code
078.11
Time-
dependent
0 Age, calendar year, health
department
Lamb et al. (2017)
[16]
Sweden Retrospective cohort study using national
registries
10–19 10–27 2: 79,042
3: 185,456
First diagnosis of ICD-10 code A63.0
or podophyllotoxin/ imiquimod
prescription
Time-
dependent
0 Age at outcome, time between
doses
Cervical abnormalities
Quadrivalent vaccine
Gertig et al.
(2013)
[17]
Australia Retrospective cohort study using linked
data from registries
12–19 12–21 0: 14,085
1: 1422
2: 2268
3: 21,151
Histology: CIN3/AIS, CIN2, CIN1, any
high grade
Cytology: low grade and high grade
Time-
dependent
Final status
0 Age at first screen, remoteness
area, SES
Crowe et al.
(2014)
[18]
Australia Case control study using linked data from
registries
12–26 11–31 0: 53,761
1: 9649
2: 10,950
3: 23,106
Histology: CIN2+/AIS Final status 0, 1, 6, 12 Year of birth, remoteness area,
SES, follow-up time
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Table 1 (continued)
Endpoint/vaccine/
reference
Country Study design Study population
Age (years) at
Vaccination Case definition Statistical analyses
Vaccination Outcome N by dose
number
Assignment
of dose
number
Buffer
periodsa
(months)
Adjustment or stratification
Brotherton et al.
(2015)
[19]
Australia Retrospective cohort study using linked
regional data registries
12–26 12–30 0: 133,055
1: 20,659
2: 27,500
3: 108,264
Histology: CIN3/AIS, CIN2, any high
grade
Cytology: low grade and high grade
Final status 0, 1, 6, 12,
24
Age, remoteness, SES, screening
start (before or after
vaccination)
Hofstetter et al.
(2016)
[20]
United
States
Retrospective cohort study using medical
center records
11–20 11–27 0: 1632
1: 695
2: 604
3: 1196
Cytology: low grade and high gradef Final status 1 Age, insurance, language, clinic
type, CT screening, and baseline
cytology
Kim et al. (2016)
[21]
Canada Nested case-control study using linked data
from registries
10–15 18–21 0: 5712
1: 327
2: 490
3: 3675
Cytology: low grade and high gradeg Final status 0 Age, urban/rural, neighborhood
income
Bivalent vaccine
Pollock et al.
(2014)
[22]
Scotland Retrospective cohort study using linked
national registry data
15–17 20–21 0: 75,113
1: 1315
2: 2725
3: 25,898
Histology: CIN1, CIN2, CIN3 Final status 0 Age, birth year cohort year,
deprivation score
Abbreviations: CT, chlamydia; SES, socioeconomic status, CIN, cervical intraepithelial neoplasia; CIN2+, CIN grade 2 or worse; AIS, adenocarcinoma in situ; ICD-9, International Classification of Disease, ninth revision; NA, not
available
a Buffer period is the lag time between vaccination and counting of outcomes.
b By multimetrix HPV assay detecting 24 types including all established high risk types.
c By Optiplex HPV assay detecting 24 types including all established high risk types.
d Three possible scenarios: (a) 1 diagnosis of ICD-9 code 078.1; (b)1 diagnosis of ICD-9 code 078.1, 078.10, 078.19 plus destruction/excision procedure or ICD-9 code 211.4, 216.5, 221.8, 222.9; (c) 1 prescription for anogenital
warts plus destruction/excision procedure or ICD-9 code 211.4, 216.5, 221.8, 222.9.
e Presented as person-years in this article.
f Low-grade cytology defined as atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. High-grade cytology defined as atypical squamous cells, cannot rule out a high-grade lesion, or
high-grade squamous intraepithelial lesion.
g High-grade cytology defined as possible high-grade squamous intraepithelial lesion (HSIL), HSIL, HSIL with possible microinvasion/invasion, squamous cell carcinoma, possible high-grade endocervical glandular lesion, AIS, AIS
with possible microinvasion/invasion and adenocarcinoma. Low-grade cytology defined as possible low-grade squamous intraepithelial lesions (LSIL), LSIL and atypical endocervical cells of uncertain significance.
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Table 2
Studies that evaluated HPV vaccine effectiveness by number of doses: analyses and main findings.
Endpoint/vaccine/
reference
Study population
Age (years) at
Buffera (months) Sensitivity analyses by
age group/buffer/dose
intervalb
Formal
comparison
of 3 vs 2 or
1 doses
Main findings
Vaccination Outcome
HPV prevalence
Bivalent vaccine
Kavanagh et al. (2014)
[9]
15–17 20–21 0 Yes/No/No No  Statistically significant effectiveness for 3, but not 2 or 1 doses compared to 0
3: aOR = .43 (CI .34, .55); 2: aOR = .68 (CI .42, 1.12); 1: aOR = .95 (CI .51, 1.76)
 Effectiveness CI overlap for 3, 2 and 1 doses
 Similar results when stratified by age at vaccination
Cuschieri et al. (2016)
[10]
15–17 20–21 0 No/No/No No  Statistically significant effectiveness for 3, 2 and 1 doses compared to 0
3: aOR = .27 (CI .20, .37); 2: aOR = .45 (CI .29, .69), 1: aOR = .52 (CI .31, .83)
 Effectiveness CI overlap for 3, 2 and 1 doses
Anogenital warts
Quadrivalent vaccine
Herweijer et al. (2014)
[11]
10–19 10–24 3 Yes/Yes/No Yes  Statistically significant effectiveness for 3, 2 and 1 doses compared to 0
3: aRR = .20 (CI .17, .23), 2: aRR = .32 (CI .26, .40), 1: aRR = .54 (CI .43, .68)
 Significantly higher effectiveness of 3 compared to 2 and 1 doses
 With buffer periods > 4 months, no significant difference between 3 and 2 doses
 Similar results for age groups 10–16 and 17–19, except effectiveness for 1 dose without
buffer period statistically significant for 10–16 year-olds
Blomberg et al. (2015)
[12]
12–27 12–27 1 Yes/No/Yes Yes  Statistically significant effectiveness for 1 compared to 0 dose, RR = .51 (CI .46, .56)
 Effectiveness not reported for 3 and 2 doses compared to 0
 Effectiveness significantly increased with each dose: RR 2 vs 1 dose = .44 (CI .37, .51); RR
3 vs 2 doses = .46 (CI .39, .54)
 With dose interval > 4 months, no significant difference between 3 and 2 doses
 Similar results when stratified by age at vaccination
Dominiak-Felden et al.
(2015)
[13]
10–23 16–23 1 No/No/No No  Statistically significant effectiveness for 3 and 2 doses, but not 1 compared to 0
3: aRR = .12 (CI .07, .21); 2: aRR = .34 (CI .14, .83); 1: aRR = .63 (CI .35, 1.16)
 Effectiveness CI overlap for 3 and 2 doses; no overlap for 3 and 1 doses
Perkins et al. (2017)
[14]
9–25 9–25 0 No/Yes/Yes Yes  Statistically significant effectiveness for 3 doses compared to 0, aRR = .52 (CI .46, .60)
 Effectiveness not reported for 2 and 1 doses compared to 0
 Higher effectiveness for 3 compared with 1 doses, aRR = .82 (CI .71, .95); but no signif-
icant difference between 3 and 2 doses, aRR = .89 (CI .78, 1.03)
 With buffer period of 1 year, no change in findings (data not shown)
 Similar results with dose interval > 5 months for 2 doses
Navarro-Illana et al.
(2017)
[15]
14 14–19 0 No/No/No No  Statistically significant effectiveness for 3, 2, and 1 doses compared to 0
3: aRR = .24 (CI .15, .34); 2: aRR = .36 (CI .14, .68); 1: aRR = .39 (CI .13, .80)
 Effectiveness CI overlap for 3, 2 and 1 doses
Lamb et al. (2017)
[16]
10–19 10–27 0 Yes/No/Yes Yes  Effectiveness not reported for 3, 2 and 1 doses compared to 0
 Higher effectiveness of 3 doses compared to 2 doses, when 2 doses administered either
0–3 months or  8 months apart; whereas no significant difference between 3 and 2
doses when the 2 doses administered within 4–7 months
 Similar results when stratified by age at vaccination
Cervical abnormalitiesc
Quadrivalent vaccine
Gertig et al. (2013)
[17]
12–19 12–21 0 No/No/No No Outcome summarized: CIN3/AIS
 Statistically significant effectiveness for 3, but not 2 and 1 doses compared to 0
3: aRR = .53 (CI .36, .77); 2: aRR = .87 (CI .46, 1.67); 1: aRR = 1.40 (CI .75, 2.61)
 Effectiveness CI overlap for 3, 2 and 1 doses
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Table 2 (continued)
Endpoint/vaccine/
reference
Study population
Age (years) at
Buffera (months) Sensitivity analyses by
age group/buffer/dose
intervalb
Formal
comparison
of 3 vs 2 or
1 doses
Main findings
Vaccination Outcome
Crowe et al. (2014)
[18]
12–26 11–31 0 Yes/Yes/No No Outcome summarized: High grade histological lesions
 Statistically significant effectiveness for 3 and 2 doses, but not 1 compared to 0
3: aOR = .54 (CI .43, .67); 2: aOR = .79 (CI .64, .98); 1: aOR = .95 (CI .77, 1.16)
 Effectiveness CI overlap for 3 and 2 doses, no overlap for 3 and 1 doses
 Buffer periods from 1 to 12 months - no consistent impact on 3, 2 and 1 dose effective-
ness estimates
 Similar results when stratified by age at vaccination
Brotherton et al. (2015)
[19]
12–26 12–30 0 Yes/Yes/Yes No Outcome summarized: CIN3/AIS
 Statistically significant effectiveness for 3, but not 2 and 1 doses compared to 0
3: aRR = .69 (CI .58, .81); 2: aRR = 1.17 (CI .92, 1.48); 1: aRR = 1.41 (CI 1.12, 1.77)
 Effectiveness CI for 3, 2 and 1 doses do not overlap
 With increasing buffer periods, some effectiveness for 2 and 1 doses in several age
groups
 No difference in effectiveness by interval between 2 doses
 Similar results when stratified by age at vaccination
Hofstetter et al. (2016)
[20]
11–20 11–27 1 Yes/No/No No Outcome summarized: Any abnormal cytology
 Statistically significant effectiveness for 3 and 2, but not 1 dose compared to 0
3: aRR = .58 (CI .48, .69); 2: aRR = .81 (CI .66, .99); 1: aRR = 1.05 (CI .88, 1.26)
 Effectiveness CI overlap for 3, 2 and 1 doses
 Similar results when stratified by age at vaccination, although effectiveness of 2 doses
compared to 0 not always significant
Kim et al. (2016)
[21]
10–15 18–21 0 No/No/No No Outcome summarized: High grade cytology
 Statistically significant effectiveness for 3, but not 2 and 1 doses compared to 0
3: aOR = .48 (CI .28, .81); 2: aOR = .17 (CI .02, 1.20); 1: aOR = .45 (CI .11, 1.83)
 Effectiveness CI overlap for 3, 2 and 1 doses
Bivalent vaccine
Pollock et al. (2014)
[22]
15–17 20–21 0 No/No/No No Outcome summarized: CIN3
 Statistically significant effectiveness for 3, but not 2 and 1 doses compared to 0
3: aRR = .45 (CI .35, .58); 2: aRR = .77 (CI .49, 1.21); 1: aRR = 1.42 (CI .89, 2.28)
 Effectiveness CI overlap for 3 and 2 doses, no overlap for 3 and 1 doses
Abbreviations: RR, relative risk; aRR, adjusted RR; aOR, adjusted odds ratio; CI, 95% confidence intervals; CIN3, cervical intraepithelial neoplasia grade 3; AIS, adenocarcinoma in situ
a Buffer period is the lag time between vaccination and counting of outcomes. This column shows buffer period in main analysis.
b Interval between doses for 2-dose vaccine recipients.
c Several outcomes were presented in some articles for cervical cytological or histological abnormalities. We summarized results for the outcome most proximal to cervical cancer.
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istered 0–3 months apart, but not when the interval was 4–7
months. Effectiveness of three, two or one doses compared with
no dose was not reported.
A study using a commercially available claims database in the
United States determined vaccine effectiveness among girls contin-
uously enrolled since January 2007 [14]. For three doses compared
with no dose, the aRR was 0.52 (95% CI 0.46, 0.60). Data were not
reported for one or two doses compared with no dose. While
higher effectiveness was found for three doses compared with
one dose, aRR = 0.82 (95% CI 0.71, 0.95), the difference between
three and two doses, aRR = 0.89 (95% CI 0.78, 1.03), did not reach
statistical significance. In the main analysis, exposure time was
counted starting after the last dose; reported findings did not
change when a one year buffer period was used. The study also
examined interval between doses. Among two-dose vaccine recip-
ients, there was no difference in incidence among those who
received doses at an interval of <5 months or 5 months.
In a study from Belgium, using an insurance database, statisti-
cally significant effectiveness was found for three doses, aRR =
0.12 (95% CI 0.07, 0.21); and two doses, aRR = 0.34 (95% CI 0.14,
0.83); but not for one dose, aRR = 0.63 (95% CI 0.35, 1.16) [13].
There was no formal statistical comparison of three vs fewer doses;
confidence intervals of three and two dose effectiveness
overlapped.
In Spain, quadrivalent HPV vaccine was used for only two years,
and in a narrowly focused target age group, before switching to
bivalent HPV vaccine. In an effectiveness study, quadrivalent vac-
cine recipients had initiated vaccination at age 14 years [15]. Com-
pared with no dose, statistically significant effectiveness was
reported for three, aRR = 0.24 (95% CI 0.15, 0.34); two, aRR = 0.36
(95% CI 0.14, 0.68); and one dose, aRR = 0.39 (95% CI 0.13, 0.80).
There was no formal statistical comparison of three vs fewer doses.
The confidence intervals for three, two, and one dose effectiveness
estimates overlapped. There were few anogenital wart diagnoses in
one- and two-dose vaccine recipients, precluding evaluation of dif-
ferent buffer periods or varying time between two doses. However,
while case counting started after the last dose, time between the
last dose and first genital wart diagnosis was at least one year in
all but one case.
In summary, among six studies evaluating quadrivalent HPV
vaccine effectiveness for prevention of anogenital warts, four
included a comparison of three, two and one doses with no dose;
all found highest effectiveness with three doses, and lower but sig-
nificant effectiveness with two doses. Three of the four studies
found significant effectiveness with one dose [11,12,15]. Four stud-
ies also formally compared three and two doses, finding either no
significant difference in the primary analysis or in analyses with
different buffer periods or two-dose intervals [11,12,14,16]. Two
studies examined different buffer periods; a longer buffer period
decreased differences in effectiveness between three and two
doses in one study [11]. In the three studies that explored intervals
between doses in two-dose vaccine recipients [12,14,16] one found
no difference between three doses and two doses with an interval
longer than four months [12]. Another study found that effective-
ness of two doses administered at a four to seven month interval
was similar to the standard three-dose schedule [16].
Of note, two studies were able to examine impact of bivalent
HPV vaccine, because both bivalent and quadrivalent HPV vaccines
had been used in the countries (Spain and Belgium) [13,15]. No
reduction in anogenital warts was observed after bivalent vaccina-
tion in either study.
3.3. Cervical cytological histological abnormalities
Six studies evaluated vaccine effectiveness for prevention of
cervical cytological or histological abnormalities, including five
for quadrivalent vaccine and one for bivalent vaccine. Outcomes
assessed were based on histology only (two), cytology only
(two), and both cytology and histology (two). Histological abnor-
malities evaluated included cervical intraepithelial neoplasia
(CIN) grade 1, 2 and 3 or CIN2+ (CIN grade 2 or worse or adenocar-
cinoma in situ [AIS]) and CIN3/AIS. All studies described character-
istics of women by number of doses, with most reporting some
differences, particularly for age at first vaccine dose; all adjusted
analyses for age at vaccination as well as limited other characteris-
tics (Table 1).
Three of the four studies evaluating abnormal histology were
conducted in Australia, a country that had achieved high vaccina-
tion coverage in routine and catchup age groups [17–19]. Two
studies included women vaccinated at a wide age range and strat-
ified results by age at first vaccination [18,19]. In a retrospective
cohort study, statistically significant effectiveness against CIN3/
AIS was observed for three doses, aRR = 0.53 (95% CI 0.36, 0.77),
but not for two doses, aRR = 0.87 (95% CI 0.46, 1.67), or one dose,
aRR = 1.40 (95% CI 0.75, 2.61) [17]. There was no formal statistical
comparison of three vs fewer doses. Results were similar for any
high grade lesion. The second study was a nested case-control
study [18]. Statistically significant effectiveness was reported for
prevention of high grade histological lesions for three doses, aOR
= 0.54 (95% CI 0.43, 0.67), and for two doses, aOR = 0.79 (95% CI
0.64, 0.98), but not for one dose, aOR = 0.95 (95% CI 0.77, 1.16).
There was no formal statistical comparison of three vs fewer doses.
The results were generally similar when stratified by age at vacci-
nation. A buffer period of 1 to 12 months had little impact on
three-dose vaccine effectiveness estimates but increased estimates
in some age strata for one and two doses (Appendix).
In the third study from Australia, Brotherton et al. assessed
effectiveness against cervical histological and cytological abnor-
malities, included varying buffer periods and also stratified by vac-
cination before or after the first cervical cancer screen [19]. Among
women vaccinated before their first screen, there was statistically
significant effectiveness against CIN3/AIS for three doses compared
with no dose, aRR = 0.69 (95% CI 0.58, 0.81), but not for two doses,
aRR = 1.17 (95% CI 0.92, 1.48), or one dose, aRR = 1.41 (1.12, 1.77).
With increasing length of buffer period, some effectiveness for two
and one doses in several age groups was observed (Appendix).
There was no difference in effectiveness of two doses with an inter-
val of >6 months vs <6 months, regardless of the buffer period.
The one study that evaluated histological abnormalities after
bivalent vaccine was conducted in Scotland [22]. Three-dose biva-
lent vaccine recipients had a lower risk of CIN3 compared with
those unvaccinated, aRR = 0.45 (95% CI 0.35, 0.58). There was no
significant effectiveness after two doses, aRR = 0.77 (95% CI 0.49,
1.21) or 1 dose, aRR = 1.42 (95% CI 0.89, 2.28). There was no formal
statistical comparison of three vs fewer doses.
Two studies exclusively evaluated cervical cytological out-
comes. Hofstetter et al. evaluated reduction in any cervical cytolog-
ical abnormality among women at U.S. community health clinics
using data from medical systems registries [20]. For those vacci-
nated at age 11–20 years, statistically significant effectiveness
was observed for three doses, aRR = 0.58 (95% CI 0.48, 0.69), and
two doses, aRR = 0.81 (95% CI 0.66, 0.99), but not one dose, aRR
= 1.05 (95% CI 0.88, 1.26). There was no formal statistical compar-
ison of three vs fewer doses. Point estimates of effectiveness varied
by age at vaccination but the findings by number of doses were
generally similar. In a study from Canada, Kim et al. presented
any, low grade, and high grade abnormal cytology results sepa-
rately [21]. While point estimates varied by outcome, the results
were similar in that statistically significant effectiveness was found
only with three doses. For high grade cytological abnormalities
results were: three doses, aOR = 0.48 (95% CI 0.28, 0.81); two doses,
aOR = 0.17 (95% CI 0.02, 1.20); and one dose, aOR = 0.45 (95% CI
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0.11, 1.83). In contrast, the two studies from Australia that evalu-
ated cytological results found three, two and one dose effective-
ness against low grade[17,19] or high grade abnormalies[19] and
a dose response was not observed.
In summary, among six studies evaluating vaccine effectiveness
for prevention of cervical cytological (four) or histological abnor-
malities (four), all found effectiveness for three doses. Women
who received less than three doses were different than three-
dose vaccine recipients in many studies, and investigators con-
ducted stratified and/or adjusted analysis to control for these dif-
ferences. Four studies found some effectiveness for prevention of
high grade histological abnormalities with two doses, and two
studies found effectiveness with one dose, in some age groups, in
analyses with longer buffer periods [18,19]. Most two-dose vaccine
recipients received two doses at a one- or two-month interval. A
longer interval between two doses had no impact on the effective-
ness estimate in the one study that examined this [19].
4. Discussion
In this systematic review of HPV vaccine effectiveness by
number of doses, most of the 14 studies found the highest point
estimate of effectiveness with three doses, followed by two
doses, and one dose. However, few studies directly compared
three, two and one dose(s) and some effectiveness estimates
had wide confidence intervals due to the small number of out-
comes in one- and two-dose vaccine recipients. All found statis-
tically significant effectiveness for three doses and 11 studies
found effectiveness for two doses [10–20]. In six studies signifi-
cant effectiveness was observed for one dose in some analyses
[10–12,15,17,19].
Variation in effectiveness by number of doses was observed
across all endpoints (prevalence, anogenital warts and cervical
abnormalities). There were generally consistent findings regarding
buffer periods in the studies that evaluated this, with three of four
studies finding higher effectiveness estimates for one and two
doses and a decrease in the differences by number of doses with
longer buffer periods. Among studies presenting results stratified
by age group, higher effectiveness estimates were generally found
with younger age at vaccination, although the differences were not
formally tested. There were differences in the impact of varying
time interval between two doses. Two studies of anogenital warts
found higher two-dose effectiveness with increasing interval
through six or seven months [11,16]. The one study of cervical
abnormalities that evaluated interval between two doses did not
find a difference [19].
Findings in these studies are, in large part, different from what
might be expected based on immunogenicity trials which showed
non-inferiority of two compared with three doses, and other stud-
ies which suggest efficacy with a single dose. However, there are
several important caveats that need to be considered when inter-
preting the findings. Firstly, the post-licensure studies were all
conducted in settings of a national three-dose recommendation
and girls who received one or two doses differed from those com-
pleting the recommended schedule. Most of the studies included
girls who were vaccinated beyond the routine target age group,
in the early years of the vaccination programs when catch-up pro-
grams had been implemented. In several studies, fewer than three-
dose vaccine recipients were older than three-dose vaccine recipi-
ents at the time of vaccination, had lower socio-economic status,
and/or had indicators of earlier sexual exposure (e.g., younger cer-
vical screening, vaccination at a family planning clinic, screening
for a sexually transmitted infection). Thus, girls who received
fewer doses were at higher risk of HPV infection, which biases
results towards a greater effectiveness of three doses compared
to one or two doses. Although most studies adjusted analyses for
some risk factors, it is likely that residual confounding remained.
Secondly, in retrospective studies it is impossible to identify
individuals who were already infected with HPV at the time of vac-
cination. The proportion of individuals already infected increases
with older age at vaccination. Since girls vaccinated with one or
two doses in the studies were often older when vaccinated and
had indicators of earlier sexual exposure, prevalent infections at
the time of vaccination would bias towards lower vaccine effec-
tiveness of one and two doses (compared with three doses). To
overcome the problem of prevalent infections, some researchers
introduced buffer periods in their analyses, which delay case
counting to exclude conditions caused by a prevalent infection.
In Herweijer et al. the effectiveness of one dose compared to no
vaccination increased with increasing buffer period and the differ-
ence between the effectiveness of three and two doses decreased
[11]. With a buffer period of one month, the effectiveness of one
dose compared to no vaccination increased to 28%, and to >50%
with buffer periods > four months. Brotherton et al. also evaluated
different buffer periods in a study of effectiveness for cervical
lesions, showing that effectiveness increased with longer buffer
periods [19]. One study of genital warts reported no effect of buffer
periods, although data were not shown [14].
Longer buffer periods might be more helpful for evaluation of
vaccine effectiveness against cervical high grade histological
abnormalities than anogenital warts, since the former take more
time to develop after infection [23]. In addition, buffer periods
could be of greater importance based on age at vaccination. There-
fore, the impact of buffer periods could vary across studies. While
ideally buffer periods should be explored for effectiveness studies,
they reduce the number of person-years with one or two doses,
which is generally small in post-licensure studies; this results in
low statistical power (i.e., insufficient power to detect statistically
significant differences in effectiveness between one, two and three
doses).
Thirdly, since all post-licensure studies published to date were
conducted in settings of a national three-dose recommendation,
most individuals vaccinated with two doses had received doses
at a 0–1 month or 0–2 month interval, as recommended with a
three-dose schedule. However, immunogenicity studies have
found non-inferior results with two doses compared to three doses
when the two doses were separated by about six months [3–5].
The longer interval is thought to allow maturation of B cells and
the second vaccination to act as a booster dose. Results of the
immunogenicity studies led to the recommendation for a two-
dose schedule (administered at 0, 6–12 months) for females aged
9 through 14 years old at the time of their first dose [6,7]. Although
the number of girls vaccinated with two doses separated by at least
six months was small in the post-licensure studies identified, four
studies evaluated interval between doses [12,14,16,19]. Blomberg
et al. found that as the time between dose one and two increased
from two to six months, the difference in effectiveness between
two and three doses decreased; with an interval of >four months
there was no difference [12]. However, two studies in this review
did not find that varying intervals between two doses had that
same effect [14,19]. It is possible that the finding of higher effec-
tiveness with a longer interval between two doses in these obser-
vational studies is the result of the longer interval acting as a buffer
period and is not related to the spacing between doses. If so, the
inconsistent findings by interval between doses could be due to
differing importance of buffer periods for the endpoints and age
groups evaluated.
Finally, as in all vaccine effectiveness studies, the accuracy of
vaccine history is important. Assessment of vaccination status
can be more challenging for HPV than for other vaccine pre-
ventable diseases, as the outcomes generally occurs years after
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vaccination and because vaccine registries in some countries do
not include adolescent vaccinations. Most studies included in this
review were conducted in countries with national vaccine reg-
istries. However, underreporting of vaccinations to registries can
still occur [18,19]. In studies using claims or insurance data, partic-
ularly in the United States, vaccination history could be incomplete
if girls moved or changed insurers during the vaccination series.
Incomplete vaccination histories could lead to overestimating
effectiveness of fewer than three doses.
In conclusion, most post-licensure studies examining HPV vac-
cine effectiveness by number of doses report highest effectiveness
with three doses, but some found no statistically significant differ-
ence between two and three doses. Additionally, almost half of the
studies found some effectiveness for one dose. Several biases in
currently available data impact estimates, with most biasing
two- and one-dose results away from showing effectiveness.
Future studies of real-world HPV vaccination effectiveness, exam-
ining persons vaccinated prior to sexual activity and using meth-
ods to reduce potential sources of bias, can help inform vaccine
policy.
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